CliffBio
biologic

Vonvendi

von Willebrand factor (Recombinant)

Loss of exclusivityDecember 2027projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameVonvendi
Active ingredientvon Willebrand factor (Recombinant)
Strength650IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2015
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found